Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.
- DOI
- 10.1136/bmjophth-2025-002398
- Published
- 2026 Jan 5
- Container
- BMJ open ophthalmology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjophth-2025-002398,
title = {Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.},
author = {Balser S and Capsius B and Hole R and Papp A and Preissinger N and Rozenknop A and Tiko T},
year = {2026},
journal = {BMJ open ophthalmology},
doi = {10.1136/bmjophth-2025-002398},
url = {https://doi.org/10.1136/bmjophth-2025-002398}
}RIS
TY - JOUR TI - Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. AU - Balser S AU - Capsius B AU - Hole R AU - Papp A AU - Preissinger N AU - Rozenknop A AU - Tiko T PY - 2026 JO - BMJ open ophthalmology DO - 10.1136/bmjophth-2025-002398 UR - https://doi.org/10.1136/bmjophth-2025-002398 ER -
APA
S, B., B, C., R, H., A, P., N, P., A, R., & T, T. (2026). Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.. BMJ open ophthalmology. https://doi.org/10.1136/bmjophth-2025-002398
Source records
- pubmed · retrieved 2026-09-26T07:59:12.105Z